Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen

Clinical Immunology

Volumn 122, Issue 2, 2007, Pages 163-172

  Valmori, Danila ^a   Lévy, Frédéric ^b   Godefroy, Emmanuelle ^a   Scotto, Luigi ^a   Souleimanian, Naira E ^a   Karbach, Julia ^c   Tosello, Valeria ^a   Hesdorffer, Charles S ^a   Old, Lloyd J ^a   Jager, Elke ^c   Ayyoub, Maha ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c KRANKENHAUS NORDWEST   (Germany)

Author keywords

Cancer testis antigens; CTL; Human; Immunodominance; Tumor immunity

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NY ESO 1 ANTIGEN; PROTEASOME; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNODOMINANT EPITOPES; MEMBRANE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33846132277     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.09.005     Document Type: Article

References (38)

1. Van Der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S., Chapiro J., Van Den Eynde B.J., Brasseur F., and Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188 (2002) 51-64
2. Yewdell J.W., and Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17 (1999) 51-88
3. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., Melief C.J., Oseroff C., Yuan L., Ruppert J., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153 (1994) 5586-5592
4. van der Burg S.H., Visseren M.J., Brandt R.M., Kast W.M., and Melief C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156 (1996) 3308-3314
5. Choi E.Y., Christianson G.J., Yoshimura Y., Sproule T.J., Jung N., Joyce S., and Roopenian D.C. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Immunity 17 (2002) 593-603
6. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., Salio M., Van Pel A., Man S., Bonin E., Liljestrom P., Dunbar P.R., and Cerundolo V. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168 (2002) 4391-4398
7. Neisig A., Roelse J., Sijts A.J., Ossendorp F., Feltkamp M.C., Kast W.M., Melief C.J., and Neefjes J.J. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J. Immunol. 154 (1995) 1273-1279
8. Mo A.X., van Lelyveld S.F., Craiu A., and Rock K.L. Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J. Immunol. 164 (2000) 4003-4010
9. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65 (1996) 801-847
10. Rock K.L., and Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17 (1999) 739-779
11. + T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4587-4592
12. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S.L., Williamson B., Stockert E., Pfreundschuh M., and Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1914-1918
13. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
14. Jäger E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jäger D., Arand M., Wada H., Noguchi Y., Stockert E., Old L.J., and Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187 (1998) 265-270
15. Goydos J.S., Patel M., and Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J. Surg. Res. 98 (2001) 76-80
16. Nakada T., Noguchi Y., Satoh S., Ono T., Saika T., Kurashige T., Gnjatic S., Ritter G., Chen Y.T., Stockert E., Nasu Y., Tsushima T., Kumon H., Old L.J., and Nakayama E. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 3 (2003) 10
17. Konishi J., Toyooka S., Aoe M., Omura Y., Washio K., Tsukuda K., and Shimizu N. The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol. Rep. 11 (2004) 1063-1067
18. + T cells in association with HLA-DR. J. Clin. Invest. 113 (2004) 1225-1233
19. Ayyoub M., Stevanovic S., Sahin U., Guillaume P., Servis C., Rimoldi D., Valmori D., Romero P., Cerottini J.C., Rammensee H.G., Pfreundschuh M., Speiser D., and Levy F. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168 (2002) 1717-1722
20. Valmori D., Souleimanian N.E., Hesdorffer C.S., Ritter G., Old L.J., and Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin. Immunol. 117 (2005) 24-30
21. + T cell responses in cancer patients. Clin. Immunol. 118 (2006) 188-194
22. + T cells in cancer-free individuals. Clin. Immunol. 117 (2005) 161-167
23. Gnjatic S., Nagata Y., Jager E., Stockert E., Shankara S., Roberts B.L., Mazzara G.P., Lee S.Y., Dunbar P.R., Dupont B., Cerundolo V., Ritter G., Chen Y.T., Knuth A., and Old L.J. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10917-10922
24. Benlalam H., Linard B., Guilloux Y., Moreau-Aubry A., Derre L., Diez E., Dreno B., Jotereau F., and Labarriere N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 171 (2003) 6283-6289
25. Trojan A., Schultze J.L., Witzens M., Vonderheide R.H., Ladetto M., Donovan J.W., and Gribben J.G. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6 (2000) 667-672
26. Hansson L., Rabbani H., Fagerberg J., Osterborg A., and Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 101 (2003) 4930-4936
27. Lucchiari-Hartz M., Lindo V., Hitziger N., Gaedicke S., Saveanu L., van Endert P.M., Greer F., Eichmann K., and Niedermann G. Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7755-7760
28. Culmann-Penciolelli B., Lamhamedi-Cherradi S., Couillin I., Guegan N., Levy J.P., Guillet J.G., and Gomard E. Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J. Virol. 68 (1994) 7336-7343
29. Meister G.E., Roberts C.G., Berzofsky J.A., and De Groot A.S. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13 (1995) 581-591
30. Kim S.K., and DeMars R. Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr. Opin. Immunol. 13 (2001) 429-436
31. + T cells in the context of HLA-B51. Cancer Immun. 2 (2002) 12
32. Blazevic V., Ranki A., and Krohn K.J. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev. AIDS Res. Hum. Retroviruses 11 (1995) 1335-1342
33. + T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J. Immunol. 164 (2000) 1529-1537
34. Zeng G., Aldridge M.E., Wang Y., Pantuck A.J., Wang A.Y., Liu Y.X., Han Y., Yuan Y.H., Robbins P.F., Dubinett S.M., deKernion J.B., and Belldegrun A.S. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int. J. Cancer 114 (2005) 268-273
35. Hughes A.L., and Hughes M.K. Self peptides bound by HLA class I molecules are derived from highly conserved regions of a set of evolutionarily conserved proteins. Immunogenetics 41 (1995) 257-262
36. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001) 255-258
37. + T cell response to a subdominant tumor antigen epitope. J. Immunol. 175 (2005) 700-712
38. Wang R.F., Johnston S.L., Zeng G., Topalian S.L., Schwartzentruber D.J., and Rosenberg S.A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161 (1998) 3598-3606